REFERENCES
- Cabezudo E., Carrara P., Morilla R., Matutes E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 1999; 84: 413–418, [PUBMED], [INFOTRIEVE], [CSA]
- Caligaris-Cappio F., Hamblin T. J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J. Clin. Oncol. 1999; 17: 399–408, [PUBMED], [INFOTRIEVE], [CSA]
- Casali P., Notkins A. L. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 1989; 10: 364–368, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- D'Arena G., Musto P., Cascavilla N., Dell'Olio M., Di Renzo N., Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B‐cell chronic lymphoproliferative disorders. Am. J. Hematol. 2000; 64: 275–281, [CROSSREF], [CSA]
- Davis K. A., Abrams B., Iyer S. B., Hoffman R. A., Bishop J. E. Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation. Cytometry 1998; 33: 197–205, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Farahat N., Lens D., Zomas A., Morilla R., Matutes E., Catovsky D. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br. J. Haematol. 1995; 91: 640–646, [PUBMED], [INFOTRIEVE], [CSA]
- Ferrand V. L., Montero Julian F. A., Chauvet M. M., Hirn M. H., Bourdeaux M. J. Quantitative determination of the MDR-related P-glycoprotein, Pgp 170, by a rapid flow cytometric technique. Cytometry 1996; 23: 120–125, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol. 1998; 51: 364–369, [PUBMED], [INFOTRIEVE], [CSA]
- Gratama J. W., D'Hautcourt J L., Mandy F., Rothe G., Barnett D., Janossy G., Papa S., Schmitz G., Lenkei R. Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis. Cytometry 1998; 33: 166–178, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Greaves M. F., Brown G., Rapson N. T., Lister T. A. Antisera to acute lymphoblastic leukemia cells. Clin. Immunol. Immunopathol. 1975; 4: 67–84, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Griffiths G. L., Govindan S. V., Sharkey R. M., Fisher D. R., Goldenberg D. M. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J. Nucl. Med. 2003; 44: 77–87, [PUBMED], [INFOTRIEVE], [CSA]
- Hagberg H., Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br. J. Haematol. 2001; 115: 609–611, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hahn G., Meeker W. Statistical Intervals: A Guide for Practitioners. John Wiley & Sons, Inc. 1991
- Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392, [PUBMED], [INFOTRIEVE], [CSA]
- Hekman A., Honselaar A., Vuist W. M., Sein J. J., Rodenhuis S., ten Bokkel Huinink W. W., Somers R., Rumke P., Melief C. J. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol. Immunother. 1991; 32: 364–372, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Henderson L. O., Marti G. E., Gaigalas A., Hannon W. H., Vogt R. F., Jr. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry 1998; 33: 97–105, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hsi E. D., Kopecky K. J., Appelbaum F. R., Boldt D., Frey T., Loftus M., Hussein M. A. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br. J. Haematol. 2003; 120: 1017–1025, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jennings C. D., Foon K. A. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90: 2863–2892, [PUBMED], [INFOTRIEVE], [CSA]
- Lauria F., Lenoci M., Annino L., Raspadori D., Marotta G., Bocchia M., Forconi F., Gentili S., La Manda M., Marconcini S., Tozzi M., Baldini L., Zinzani P. L., Foa R. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046–1050, [PUBMED], [INFOTRIEVE], [CSA]
- Lenkei R., Gratama J. W., Rothe G., Schmitz G., D'Hautcourt J. L., Arekrans A., Mandy F., Marti G. Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry 1998; 33: 188–196, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lopez-Matas M., Rodriguez-Justo M., Morilla R., Catovsky D., Matutes E. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haematologica 2000; 85: 1140–1145, [PUBMED], [INFOTRIEVE], [CSA]
- Maloney D. G., Grillo-Lopez A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195, [PUBMED], [INFOTRIEVE], [CSA]
- Maloney D. G., Liles T. M., Czerwinski D. K., Waldichuk C., Rosenberg J., Grillo-Lopez A., Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466, [PUBMED], [INFOTRIEVE], [CSA]
- McLaughlin P., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16: 2825–2833, [PUBMED], [INFOTRIEVE], [CSA]
- Molica S., Levato D., Dattilo A., Mannella A. Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur. J. Haematol. 1998; 60: 47–52, [PUBMED], [INFOTRIEVE], [CSA]
- Morabito F., Mangiola M., Rapezzi D., Zupo S., Oliva B. M., Ferraris A. M., Spriano M., Rossi E., Stelitano C., Callea V., Cutrona G., Ferrarini M. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica 2003; 88: 864–873, [PUBMED], [INFOTRIEVE], [CSA]
- Murray J. L. Monoclonal antibody treatment of solid tumors: a coming of age. Semin. Oncol. 2000; 27: 64–70, discussion 92–100[PUBMED], [INFOTRIEVE], [CSA]
- Nguyen D. T., Amess J. A., Doughty H., Hendry L., Diamond L. W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol. 1999; 62: 76–82, [PUBMED], [INFOTRIEVE], [CSA]
- Poncelet P., Carayon P. Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J. Immunol. Meth. 1985; 85: 65–74, [CROSSREF], [CSA]
- Press O. W., Howell-Clark J., Anderson S., Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83: 1390–1397, [PUBMED], [INFOTRIEVE], [CSA]
- Sapra P., Allen T. M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002; 62: 7190–7194, [PUBMED], [INFOTRIEVE], [CSA]
- Schwartz A., Fernandez-Repollet E., Vogt R., Gratama J. W. Standardizing flow cytometry: construction of a standardized fluorescence calibration plot using matching spectral calibrators. Cytometry 1996; 26: 22–31, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schwartz A., Gaigalas A. K., Wang L., Marti G. E., Vogt R. F., Fernandez-Repollet E. Formalization of the MESF unit of fluorescence intensity. Cytometry B Clin Cytom. 2004; 57: 1–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Serke S., van Lessen A., Huhn D. Quantitative fluorescence flow cytometry: a comparison of the three techniques for direct and indirect immunofluorescence. Cytometry 1998; 33: 179–187, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shan D., Press O. W. Constitutive endocytosis and degradation of CD22 by human B cells. J. Immunol. 1995; 154: 4466–4475, [PUBMED], [INFOTRIEVE], [CSA]
- Stewart C. C., Behm F. G., Carey J. L., Cornbleet J., Duque R. E., Hudnall S. D., Hurtubise P. E., Loken M., Tubbs R. R., Wormsley S. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry 1997; 30: 231–235, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stewart C. C., Stewart S. J. Cell preparation for the identification of leukocytes. Methods Cell Biol 2001a; 63: 217–251, [PUBMED], [INFOTRIEVE], [CSA]
- Stewart C. C., Stewart S. J. Multiparameter data acquisition and analysis of leukocytes by flow cytometry. Meth. Cell Biol. 2001b; 64: 289–312, [CSA]
- Thomas D. A., O'Brien S., Bueso-Ramos C., Faderl S., Keating M. J., Giles F. J., Cortes J., Kantarjian H. M. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906–3911, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vlasveld L. T., Hekman A., Vyth-Dreese F. A., Melief C. J., Sein J. J., Voordouw A. C., Dellemijn T. A., Rankin E. M. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol. Immunother. 1995; 40: 37–47, [PUBMED], [INFOTRIEVE], [CSA]
- Ward J. H. Autoimmunity in chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 2001; 2: 253–257, [PUBMED], [INFOTRIEVE], [CSA]